Listen to audio brief:

On May 5, 2025, the White House issued an executive order aimed at increasing domestic production of critical medicines. The order addresses regulatory barriers that have hindered pharmaceutical manufacturing in the United States, which have been exacerbated by lengthy approval processes and inspections.

Key actions include streamlining regulations, improving inspections of foreign facilities, and coordinating environmental permits to facilitate faster expansion of manufacturing capacity.

Original: article